Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma

Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma

Aberrant methylation of tumor-related genes has been identified as a promising biomarker for hepatocellular carcinoma (HCC). This study aimed to investigate the diagnostic value of SRY (sex determining region Y)-box 1 (SOX1) and Vimentin (VIM) promoter methylation for HCC. The study included 360 sub...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neoplasma 2017, Vol.64 (5), p.745-753
Hauptverfasser: Liu, X Y, Fan, Y C, Gao, S, Zhao, J, Chen, L Y, Li, F, Wang, K
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 753
container_issue 5
container_start_page 745
container_title Neoplasma
container_volume 64
creator Liu, X Y
Fan, Y C
Gao, S
Zhao, J
Chen, L Y
Li, F
Wang, K
description Aberrant methylation of tumor-related genes has been identified as a promising biomarker for hepatocellular carcinoma (HCC). This study aimed to investigate the diagnostic value of SRY (sex determining region Y)-box 1 (SOX1) and Vimentin (VIM) promoter methylation for HCC. The study included 360 subjects, 240 patients with HCC, 29 with liver cirrhosis (LC), 66 with chronic hepatitis B (CHB) and 25 healthy controls (HCs). The methylation status of SOX1 and VIM promoters in the serum was detected by methylation-specific polymerase chain reaction (MSP). The methylation frequencies of SOX1 and VIM promoters in HCC patients were significantly higher than those in LC (p
doi_str_mv 10.4149/neo_2017_513
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1907325593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1907325593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-3629b84ec4dd2e462016d8dea0fc90365d0490c25b89dd9757f49364dee199423</originalsourceid><addsrcrecordid>eNpNkDtPwzAURi0EolXpxow8MhDwM4lHVPGo1KoDD7FZju2ogSQOtjP03-OqBXGXK10dffruAeASo1uGmbjrrZME4UJyTE_AFFNaZozi4hRMESJlRvKST8A8hE-UJueIEHwOJqTkgmBSTIFe27jdtSo2roeuhi-bDwxVb-D7cg0H7zoXrQ-w6WGwfuygCnBIpz42qoVV4zrlv_ZA7Tzc2kFFp23bjq3yUCuvmz4RF-CsVm2w8-OegbfHh9fFc7baPC0X96tMU8FjRnMiqpJZzYwhluXpr9yUxipUa4Fozg1iAmnCq1IYIwpe1EzQnBlrsRCM0Bm4PuSm3t-jDVF2TdjXUUnTGCQWqKCEc0ETenNAtXcheFvLwTfpl53ESO7Nyv9mE351TB6rzpo_-Ncj_QH2U3RT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1907325593</pqid></control><display><type>article</type><title>Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma</title><source>Alma/SFX Local Collection</source><creator>Liu, X Y ; Fan, Y C ; Gao, S ; Zhao, J ; Chen, L Y ; Li, F ; Wang, K</creator><creatorcontrib>Liu, X Y ; Fan, Y C ; Gao, S ; Zhao, J ; Chen, L Y ; Li, F ; Wang, K</creatorcontrib><description><![CDATA[Aberrant methylation of tumor-related genes has been identified as a promising biomarker for hepatocellular carcinoma (HCC). This study aimed to investigate the diagnostic value of SRY (sex determining region Y)-box 1 (SOX1) and Vimentin (VIM) promoter methylation for HCC. The study included 360 subjects, 240 patients with HCC, 29 with liver cirrhosis (LC), 66 with chronic hepatitis B (CHB) and 25 healthy controls (HCs). The methylation status of SOX1 and VIM promoters in the serum was detected by methylation-specific polymerase chain reaction (MSP). The methylation frequencies of SOX1 and VIM promoters in HCC patients were significantly higher than those in LC (p<0.001 and p<0.001), CHB (p<0.001 and p<0.001) and HC (p<0.001 and p<0.001) subjects. Furthermore, hypermethylation of SOX1 and VIM promoters were found in patients with advanced TNM stage (III-IV) and larger tumor size (≥5 cm) compared with early stage (I-II) (p<0.001 and p=0.004) patients with smaller tumor size (<3 cm) (p=0.018 and p=0.001). Moreover, the VIM promoter methylation frequency was higher in patients with portal vein tumor thrombosis (PVTT) (p=0.006) and vascular invasion (p=0.003). In addition, the combination of α-fetoprotein (≥20 ng/ml) with SOX1 and VIM promoter methylation significantly improved their diagnostic value. In conclusions, aberrant methylation of SOX1 and VIM promoters may be potential biomarkers for noninvasive detection of HCC and HCC metastasis.]]></description><identifier>ISSN: 0028-2685</identifier><identifier>ISSN: 1338-4317</identifier><identifier>EISSN: 1338-4317</identifier><identifier>DOI: 10.4149/neo_2017_513</identifier><identifier>PMID: 28592127</identifier><language>eng</language><publisher>Slovakia</publisher><ispartof>Neoplasma, 2017, Vol.64 (5), p.745-753</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-3629b84ec4dd2e462016d8dea0fc90365d0490c25b89dd9757f49364dee199423</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28592127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, X Y</creatorcontrib><creatorcontrib>Fan, Y C</creatorcontrib><creatorcontrib>Gao, S</creatorcontrib><creatorcontrib>Zhao, J</creatorcontrib><creatorcontrib>Chen, L Y</creatorcontrib><creatorcontrib>Li, F</creatorcontrib><creatorcontrib>Wang, K</creatorcontrib><title>Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma</title><title>Neoplasma</title><addtitle>Neoplasma</addtitle><description><![CDATA[Aberrant methylation of tumor-related genes has been identified as a promising biomarker for hepatocellular carcinoma (HCC). This study aimed to investigate the diagnostic value of SRY (sex determining region Y)-box 1 (SOX1) and Vimentin (VIM) promoter methylation for HCC. The study included 360 subjects, 240 patients with HCC, 29 with liver cirrhosis (LC), 66 with chronic hepatitis B (CHB) and 25 healthy controls (HCs). The methylation status of SOX1 and VIM promoters in the serum was detected by methylation-specific polymerase chain reaction (MSP). The methylation frequencies of SOX1 and VIM promoters in HCC patients were significantly higher than those in LC (p<0.001 and p<0.001), CHB (p<0.001 and p<0.001) and HC (p<0.001 and p<0.001) subjects. Furthermore, hypermethylation of SOX1 and VIM promoters were found in patients with advanced TNM stage (III-IV) and larger tumor size (≥5 cm) compared with early stage (I-II) (p<0.001 and p=0.004) patients with smaller tumor size (<3 cm) (p=0.018 and p=0.001). Moreover, the VIM promoter methylation frequency was higher in patients with portal vein tumor thrombosis (PVTT) (p=0.006) and vascular invasion (p=0.003). In addition, the combination of α-fetoprotein (≥20 ng/ml) with SOX1 and VIM promoter methylation significantly improved their diagnostic value. In conclusions, aberrant methylation of SOX1 and VIM promoters may be potential biomarkers for noninvasive detection of HCC and HCC metastasis.]]></description><issn>0028-2685</issn><issn>1338-4317</issn><issn>1338-4317</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpNkDtPwzAURi0EolXpxow8MhDwM4lHVPGo1KoDD7FZju2ogSQOtjP03-OqBXGXK10dffruAeASo1uGmbjrrZME4UJyTE_AFFNaZozi4hRMESJlRvKST8A8hE-UJueIEHwOJqTkgmBSTIFe27jdtSo2roeuhi-bDwxVb-D7cg0H7zoXrQ-w6WGwfuygCnBIpz42qoVV4zrlv_ZA7Tzc2kFFp23bjq3yUCuvmz4RF-CsVm2w8-OegbfHh9fFc7baPC0X96tMU8FjRnMiqpJZzYwhluXpr9yUxipUa4Fozg1iAmnCq1IYIwpe1EzQnBlrsRCM0Bm4PuSm3t-jDVF2TdjXUUnTGCQWqKCEc0ETenNAtXcheFvLwTfpl53ESO7Nyv9mE351TB6rzpo_-Ncj_QH2U3RT</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Liu, X Y</creator><creator>Fan, Y C</creator><creator>Gao, S</creator><creator>Zhao, J</creator><creator>Chen, L Y</creator><creator>Li, F</creator><creator>Wang, K</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2017</creationdate><title>Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma</title><author>Liu, X Y ; Fan, Y C ; Gao, S ; Zhao, J ; Chen, L Y ; Li, F ; Wang, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-3629b84ec4dd2e462016d8dea0fc90365d0490c25b89dd9757f49364dee199423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, X Y</creatorcontrib><creatorcontrib>Fan, Y C</creatorcontrib><creatorcontrib>Gao, S</creatorcontrib><creatorcontrib>Zhao, J</creatorcontrib><creatorcontrib>Chen, L Y</creatorcontrib><creatorcontrib>Li, F</creatorcontrib><creatorcontrib>Wang, K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neoplasma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, X Y</au><au>Fan, Y C</au><au>Gao, S</au><au>Zhao, J</au><au>Chen, L Y</au><au>Li, F</au><au>Wang, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma</atitle><jtitle>Neoplasma</jtitle><addtitle>Neoplasma</addtitle><date>2017</date><risdate>2017</risdate><volume>64</volume><issue>5</issue><spage>745</spage><epage>753</epage><pages>745-753</pages><issn>0028-2685</issn><issn>1338-4317</issn><eissn>1338-4317</eissn><abstract><![CDATA[Aberrant methylation of tumor-related genes has been identified as a promising biomarker for hepatocellular carcinoma (HCC). This study aimed to investigate the diagnostic value of SRY (sex determining region Y)-box 1 (SOX1) and Vimentin (VIM) promoter methylation for HCC. The study included 360 subjects, 240 patients with HCC, 29 with liver cirrhosis (LC), 66 with chronic hepatitis B (CHB) and 25 healthy controls (HCs). The methylation status of SOX1 and VIM promoters in the serum was detected by methylation-specific polymerase chain reaction (MSP). The methylation frequencies of SOX1 and VIM promoters in HCC patients were significantly higher than those in LC (p<0.001 and p<0.001), CHB (p<0.001 and p<0.001) and HC (p<0.001 and p<0.001) subjects. Furthermore, hypermethylation of SOX1 and VIM promoters were found in patients with advanced TNM stage (III-IV) and larger tumor size (≥5 cm) compared with early stage (I-II) (p<0.001 and p=0.004) patients with smaller tumor size (<3 cm) (p=0.018 and p=0.001). Moreover, the VIM promoter methylation frequency was higher in patients with portal vein tumor thrombosis (PVTT) (p=0.006) and vascular invasion (p=0.003). In addition, the combination of α-fetoprotein (≥20 ng/ml) with SOX1 and VIM promoter methylation significantly improved their diagnostic value. In conclusions, aberrant methylation of SOX1 and VIM promoters may be potential biomarkers for noninvasive detection of HCC and HCC metastasis.]]></abstract><cop>Slovakia</cop><pmid>28592127</pmid><doi>10.4149/neo_2017_513</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-2685
ispartof Neoplasma, 2017, Vol.64 (5), p.745-753
issn 0028-2685
1338-4317
1338-4317
language eng
recordid cdi_proquest_miscellaneous_1907325593
source Alma/SFX Local Collection
title Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A10%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylation%20of%20SOX1%20and%20VIM%20promoters%20in%20serum%20as%20potential%20biomarkers%20for%20hepatocellular%20carcinoma&rft.jtitle=Neoplasma&rft.au=Liu,%20X%20Y&rft.date=2017&rft.volume=64&rft.issue=5&rft.spage=745&rft.epage=753&rft.pages=745-753&rft.issn=0028-2685&rft.eissn=1338-4317&rft_id=info:doi/10.4149/neo_2017_513&rft_dat=%3Cproquest_cross%3E1907325593%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1907325593&rft_id=info:pmid/28592127&rfr_iscdi=true